XML 65 R58.htm IDEA: XBRL DOCUMENT v3.25.3
Collaboration and License Agreements - Additional Information (Details) - USD ($)
shares in Millions
 1 Months Ended 3 Months Ended 9 Months Ended
Oct. 10, 2025
Oct. 31, 2023
Sep. 30, 2022
Dec. 31, 2021
Jun. 30, 2021
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Dec. 31, 2024
Jun. 30, 2022
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Current portion of deferred revenue           $ 110,320,000   $ 110,320,000   $ 108,858,000  
Long-term portion of deferred revenue           10,160,000   10,160,000   $ 33,218,000  
Lilly Agreement                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Agreement description   In October 2023, the Company entered into a Transfer and Delegation Agreement, or the Lilly Agreement, with Eli Lilly and Company, or Lilly, pursuant to which Lilly acquired certain assets and other rights under the Company’s amended collaboration and license agreement, or the Verve Agreement, with Verve, including the Company’s opt-in rights to co-develop and co-commercialize Verve’s base editing programs for cardiovascular disease (see discussion below related to the Verve Agreement). The Company granted Lilly an exclusive sublicense to the Verve technology originally licensed to the Company under the Verve Agreement. Lilly also acquired the right to receive any future milestone or royalty payments payable by Verve under the Verve Agreement and the rights and obligations to designate representatives and participate on the joint steering committee with Verve. The Company received a $200.0 million nonrefundable upfront payment and is eligible to receive up to $350.0 million in potential future development-stage payments upon the completion of certain clinical, regulatory and alliance events, of which $25.0 million has been received through September 30, 2025.                  
Collaboration agreement upfront payment received   $ 200,000,000                  
Collaboration agreement milestones payment received           25,000,000   25,000,000      
Collaboration agreement performance obligation revenue recognized           0   0      
Deferred revenue liability           0   0      
Lilly Agreement | Maximum                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Additional proceeds from potential future development-stage payments   $ 350,000,000                  
Pfizer                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Agreement description       In December 2021, the Company entered into a research collaboration agreement, or the Pfizer Agreement, with Pfizer Inc., or Pfizer, focused on the use of certain of the Company’s base editing technology to develop in vivo therapies for rare genetic diseases of the liver, muscle, and central nervous system. Under the terms of the Pfizer Agreement, the Company will conduct all research activities through development candidate selection for three base editing programs that target specific genes corresponding to specific diseases that are the subject of such programs. Pfizer will have exclusive rights to license each of the three programs at no additional cost, each an Opt-In Right, and will assume responsibility for subsequent development and commercialization. At the end of the Phase 1/2 clinical trials, the Company may elect to enter into a global co-development and co-commercialization agreement with Pfizer with respect to one program licensed under the collaboration for an option exercise fee equal to a percentage of the applicable development costs incurred by Pfizer, or the Participation Election. In the event the Company elects to exercise its Participation Election, upon the payment of its option exercise fee, Pfizer and the Company would share net profits as well as development and commercialization costs in a 65%/35% (Pfizer/Company) split for such program. The research collaboration is managed on an overall basis by a Joint Research Committee, or JRC, formed by an equal number of representatives from the Company and Pfizer.              
Collaboration arrangement, initial term       4 years              
Collaboration arrangement, option to extend       The initial four year term of the collaboration extends through December 2025 with an option to extend for an additional year.              
Collaboration arrangement extension term description       extended for an additional year on a program-by-program basis              
Potential total consideration       $ 1,350,000,000              
Collaboration agreement aggregate transaction price       300,000,000              
Nonrefundable upfront payment receivable       $ 300,000,000              
Collaboration agreement performance obligation revenue recognized           0 $ 2,700,000 0 $ 8,400,000    
Earn-out payment period       10 years              
Current portion of deferred revenue           99,000,000   99,000,000      
Long-term portion of deferred revenue           10,200,000   10,200,000      
Pfizer | Assigned to Company | Upon Participation Election                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Net profits as well as development and commercialization costs percentage       35.00%              
Pfizer | Assigned to Pfizer | Upon Participation Election                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Net profits as well as development and commercialization costs percentage       65.00%              
Pfizer | Maximum | Per Program                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Development regulatory and commercial milestones receivable       $ 350,000,000              
Apellis Pharmaceuticals, Inc                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Agreement description         In June 2021, the Company entered into a research collaboration agreement, or the Apellis Agreement, with Apellis Pharmaceuticals, Inc., or Apellis, focused on the use of certain of the Company’s base editing technology to discover new treatments for complement system-driven diseases. Under the terms of the Apellis Agreement, the Company will conduct preclinical research on six base editing programs that target specific genes within the complement system in various organs, including the eye, liver, and brain. Apellis has an exclusive option to license any or all of the six programs, or in each case, an Opt-In Right, and collectively, the Opt-In Rights, and will assume responsibility for subsequent development. As of September 30, 2025, Apellis notified the Company of its decision to opt-in to one of the six base editing programs. As a result of Apellis' decision to opt-in to the program, the Company received a cash opt-in fee of $3.8 million which was recognized as revenue during the three months ended September 30, 2025. The Company may elect to enter into a 50-50 U.S. co-development and co-commercialization agreement with Apellis with respect to one program licensed under the collaboration. The collaboration is managed on an overall basis by an alliance steering committee formed by an equal number of representatives from the Company and Apellis.            
Collaboration arrangement, initial term         5 years            
Collaboration agreement performance obligation revenue period for recognition         5 years            
Collaboration agreement aggregate transaction price         $ 75,000,000            
Collaboration agreement performance obligation revenue recognized           7,600,000 8,500,000 19,300,000 16,700,000    
Upfront fee receivable upon signing contract         $ 50,000,000            
Collaboration agreement first anniversary amount receivable                     $ 25,000,000
Current portion of deferred revenue           11,300,000   11,300,000      
Apellis Pharmaceuticals, Inc | Maximum                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Collaboration arrangement extension term         2 years            
Orbital                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Agreement description     Under the terms of the Orbital Agreement, the Company collaborated with Orbital to advance nonviral delivery and ribonucleic acid, or RNA, technology by providing Orbital with certain proprietary materials, a non-exclusive research license to certain RNA technology and nonviral delivery technology controlled by the Company, and by performing research and development support services as outlined in a research plan. The Company also granted Orbital an exploitation license to certain RNA technology and nonviral delivery technology controlled by the Company. The exploitation license was exclusive in the fields of vaccines and certain protein therapeutics during the research term, and after the research term is nonexclusive in all fields other than gene editing and conditioning. The collaboration is managed on an overall basis by a Joint Steering Committee, or JSC, comprised of an equal number of representatives from the Company and Orbital.                
Common stock shares received at closing     75                
Collaboration agreement performance obligation revenue period for recognition     3 years                
Collaboration agreement aggregate transaction price     $ 25,500,000                
Collaboration agreement performance obligation revenue recognized           2,100,000 $ 2,100,000 6,400,000 $ 6,400,000    
Current portion of deferred revenue           0   $ 0      
Orbital | Subsequent Event                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Percentage of fully-diluted ownership stake 17.00%                    
Orbital | Subsequent Event | Common Stock                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Equity shares held 75                    
Orbital | Bristol Myers Squibb | Subsequent Event                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Payments to acquire businesses for cash $ 1,500,000,000                    
Orbital | Research Plan                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Collaboration arrangement, initial term     3 years                
opt-in fee | Apellis Pharmaceuticals, Inc                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Collaboration agreement performance obligation revenue recognized           3,800,000          
opt-in to one | Apellis Pharmaceuticals, Inc                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Collaboration agreement performance obligation revenue recognized           $ 3,800